| Followers | 54 |
| Posts | 6684 |
| Boards Moderated | 0 |
| Alias Born | 01/11/2017 |
Monday, May 10, 2021 9:27:22 AM
“Will apply”….”if” approved then they can sell a whopping 200k vials.
Nader professed to “will apply” in US, Mexico, UK, Canada, Spain and Italy. The reason he never “does” apply is that the data doesn’t show statistical significance. Please cite Nader Pourhasen’s own quote.
Now he’s yapping about India, another convenient pivot while Phillipines and Brazil are allegedly awaiting info.
Let’s see the Cytodyn promise list over the last 14 months:
- bring on world-renowned oncologist, Dr Pestell. At the time, touted as the savior and Nader awarded millions of bonus shares. End result- Nader keeps shares, Pestell keeps 25+ million shares, Pestell fired and counter-sued Nader and Cytodyn. Discovery will be interesting. TNMBC on severe delay!
-HIV BLA- failure!! FDA won’t file application and Nader continues to change reasoning. What was supposed to be “two weeks” to correct will be more than one year. $87M in milestone payments forfeited thus far because of that! Blame put on CRO- Nader hired CRO-
- uplist- Fail!
- EUA for Covid in USA: Fail and no EUA
- EUA in UK- Fail and didn’t even apply. CEO uses semantics to say “requested”
- EUA in Mexico after 25 patient trial- Fail! No EUA
- Alleged talks with Spain and Italy- Fail- nothing allowed
- shareholder lawsuits for unjust enrichment- Fail! Nader forced to settle
- NASH - TWO (2) patients so far!
- GvHD- scrapped after being touted as groundbreaking
- CURE for HIV in the bone marrow: uh, ok! FAIL.
- “No dilution”- Fail! Toxic lending agreement with unregistered financier (Fife) has exposed shareholders to dilution!
-triple digit stock: LOL, where do we begin
So now, we “going to apply” in Phillipines and then pivot to Brazil and India. Apparently, resident experts feel their FDA’s are less corrupt. Any empirical data to support either hypothesis?
Payments due to Samsung continue to build and the company as collateralized itself as assurance. Desperation causes bad decisions in hindsight.
$400+ million in debt per the Cytodyn filings.
($400,000,000) Debt
+ $0 Revenue
—————————————
$(400,000,000)
Generally that leads to insolvency. Chapter 11!!
Place your bets on the company’s track record thus far!
Grip
Nader professed to “will apply” in US, Mexico, UK, Canada, Spain and Italy. The reason he never “does” apply is that the data doesn’t show statistical significance. Please cite Nader Pourhasen’s own quote.
Now he’s yapping about India, another convenient pivot while Phillipines and Brazil are allegedly awaiting info.
Let’s see the Cytodyn promise list over the last 14 months:
- bring on world-renowned oncologist, Dr Pestell. At the time, touted as the savior and Nader awarded millions of bonus shares. End result- Nader keeps shares, Pestell keeps 25+ million shares, Pestell fired and counter-sued Nader and Cytodyn. Discovery will be interesting. TNMBC on severe delay!
-HIV BLA- failure!! FDA won’t file application and Nader continues to change reasoning. What was supposed to be “two weeks” to correct will be more than one year. $87M in milestone payments forfeited thus far because of that! Blame put on CRO- Nader hired CRO-
- uplist- Fail!
- EUA for Covid in USA: Fail and no EUA
- EUA in UK- Fail and didn’t even apply. CEO uses semantics to say “requested”
- EUA in Mexico after 25 patient trial- Fail! No EUA
- Alleged talks with Spain and Italy- Fail- nothing allowed
- shareholder lawsuits for unjust enrichment- Fail! Nader forced to settle
- NASH - TWO (2) patients so far!
- GvHD- scrapped after being touted as groundbreaking
- CURE for HIV in the bone marrow: uh, ok! FAIL.
- “No dilution”- Fail! Toxic lending agreement with unregistered financier (Fife) has exposed shareholders to dilution!
-triple digit stock: LOL, where do we begin
So now, we “going to apply” in Phillipines and then pivot to Brazil and India. Apparently, resident experts feel their FDA’s are less corrupt. Any empirical data to support either hypothesis?
Payments due to Samsung continue to build and the company as collateralized itself as assurance. Desperation causes bad decisions in hindsight.
$400+ million in debt per the Cytodyn filings.
($400,000,000) Debt
+ $0 Revenue
—————————————
$(400,000,000)
Generally that leads to insolvency. Chapter 11!!
Place your bets on the company’s track record thus far!
Grip
Recent CYDY News
- CytoDyn Presents New Leronlimab Data in Metastatic Colorectal Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/22/2026 12:30:00 PM
- CytoDyn Completes Enrollment in Phase 2 Metastatic Colorectal Cancer Study • GlobeNewswire Inc. • 04/21/2026 08:10:00 PM
- CytoDyn Presents New Leronlimab Data in Metastatic Triple-Negative Breast Cancer at AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/20/2026 12:30:00 PM
- CytoDyn to Present at the AACR Annual Meeting 2026 • GlobeNewswire Inc. • 04/14/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 04/08/2026 09:15:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 04/08/2026 12:30:28 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/25/2026 09:16:10 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:24:23 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:23:14 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:22:42 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:21:33 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:57 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/24/2026 09:20:20 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/24/2026 09:15:24 PM
- CytoDyn Presents at AACR Special Conference in Cancer Research: Brain Cancer • GlobeNewswire Inc. • 03/24/2026 12:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 03/09/2026 09:15:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/05/2026 01:35:02 PM
- CytoDyn Closes $17.5 Million Financing to Fund Continued Development of Leronlimab • GlobeNewswire Inc. • 03/05/2026 01:30:00 PM
- CytoDyn Presents Novel CCR5 Inhibition Mechanisms and Long-Term Survival Signals for Leronlimab in Metastatic Breast Cancer at AACR Immuno-Oncology Conference • GlobeNewswire Inc. • 02/20/2026 01:30:00 PM
- CytoDyn Announces Funding and Initiation of Expanded Access Program for Patients with Triple-negative Breast Cancer • GlobeNewswire Inc. • 01/27/2026 01:30:00 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 01/09/2026 10:15:22 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/09/2026 01:30:45 PM
- Form 424B3 - Prospectus [Rule 424(b)(3)] • Edgar (US Regulatory) • 12/22/2025 10:15:23 PM
- Form EFFECT - Notice of Effectiveness • Edgar (US Regulatory) • 12/17/2025 05:15:14 AM
- December 2025 Letter to Shareholders • GlobeNewswire Inc. • 12/16/2025 01:30:00 PM
